Figure 7. CBP1, which lack Cdk6 amplification and KRAS mutation, did not respond to either the CDK4/6 inhibitor or the MEK inhibitor.

The mild tumor growth inhibition is not statistically significant from the vehicle for all three treatment arms (P>0.05).